BRAF and glioma: Furthermore, inclusion of additional commonly used and novel emerging markers such as Ki67 tumor cell proliferation index (gliomas) [16, 17, 18], INI1 protein loss (atypical teratoid/rhabdoid tumor) [19, 20] or BRAF V600E mutation status (melanoma brain metastases) [21, 22, 23] seems desirable.